{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T23:14:34Z","timestamp":1783293274892,"version":"3.54.6"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T00:00:00Z","timestamp":1778371200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006778","name":"Georgia Institute of Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006778","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","award":["1 NU2RGH001919-01-00"],"award-info":[{"award-number":["1 NU2RGH001919-01-00"]}],"id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.vaccine.2026.128689","type":"journal-article","created":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T06:33:25Z","timestamp":1780122805000},"page":"128689","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Quantifying the benefits of improved operations for polio outbreak response: A model-based analysis"],"prefix":"10.1016","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8120-1506","authenticated-orcid":false,"given":"Yuming","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2686-546X","authenticated-orcid":false,"given":"Pinar","family":"Keskinocak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4868-5275","authenticated-orcid":false,"given":"Stephanie D.","family":"Kovacs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4073-6165","authenticated-orcid":false,"given":"Lauren N.","family":"Steimle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2026.128689_bb0005","author":"World Health Assembly"},{"key":"10.1016\/j.vaccine.2026.128689_bb0010","author":"Global Polio Eradication Initiative"},{"key":"10.1016\/j.vaccine.2026.128689_bb0015","author":"World Health Organization"},{"key":"10.1016\/j.vaccine.2026.128689_bb0020","author":"World Health Organization"},{"issue":"suppl_1","key":"10.1016\/j.vaccine.2026.128689_bb0025","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1093\/infdis\/jiw592","article-title":"Polio endgame: lessons learned from the immunization systems management group","volume":"216","author":"Zipursky","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128689_bb0030","author":"World Health Organization"},{"key":"10.1016\/j.vaccine.2026.128689_bb0035","author":"Global Polio Eradication Initiative"},{"key":"10.1016\/j.vaccine.2026.128689_bb0040","author":"Molodecky"},{"issue":"6738","key":"10.1016\/j.vaccine.2026.128689_bb0045","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1126\/science.adu6580","article-title":"Global withdrawal of Sabin oral poliovirus type 2 vaccine in 2016","volume":"387","author":"Molodecky","year":"2025","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128689_bb0050","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1016\/S1473-3099(22)00582-5","article-title":"A novel tool to eradicate an ancient scourge: the novel oral polio vaccine type 2 story","volume":"23","author":"Bandyopadhyay","year":"2023","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128689_bb0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgph.0002920","article-title":"One billion doses and WHO prequalification of nOPV2: implications for the global polio situation and beyond","volume":"4","author":"Bandyopadhyay","year":"2024","journal-title":"PLOS Global Public Health"},{"key":"10.1016\/j.vaccine.2026.128689_bb0060","author":"Global Polio Eradication Initiative"},{"issue":"34","key":"10.1016\/j.vaccine.2026.128689_bb0065","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.15585\/mmwr.mm7034a1","article-title":"Progress toward polio eradication - worldwide, January 2019-June 2021","volume":"70","author":"Bigouette","year":"2021","journal-title":"Morbidity Mortality Weekly Report (MMWR)"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128689_bb0070","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/risa.13622","article-title":"Updated characterization of outbreak response strategies for 2019-2029: impacts of using a novel type 2 oral poliovirus vaccine strain","volume":"41","author":"Kalkowska","year":"2021","journal-title":"Risk Anal"},{"issue":"Suppl. 1","key":"10.1016\/j.vaccine.2026.128689_bb0075","doi-asserted-by":"crossref","first-page":"A142","DOI":"10.1016\/j.vaccine.2022.10.060","article-title":"Outbreak response strategies with type 2-containing oral poliovirus vaccines","volume":"41 Suppl 1","author":"Kalkowska","year":"2023","journal-title":"Vaccine"},{"issue":"Suppl 1(Suppl 1)","key":"10.1016\/j.vaccine.2026.128689_bb0080","doi-asserted-by":"crossref","first-page":"A136","DOI":"10.1016\/j.vaccine.2021.04.061","article-title":"Serotype 2 oral poliovirus vaccine (OPV2) choices and the consequences of delaying outbreak response","volume":"41","author":"Kalkowska","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128689_bb0085","first-page":"1184","article-title":"A compartmental simulation model to improve interventions for controlling poliovirus outbreaks","volume":"2023","author":"Sun","year":"2023","journal-title":"Winter Simul Conf (WSC)"},{"key":"10.1016\/j.vaccine.2026.128689_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.jvacx.2024.100476","article-title":"Modeling the spread of circulating vaccine-derived poliovirus type 2 outbreaks and interventions: a case study of Nigeria","volume":"18","author":"Sun","year":"2024","journal-title":"Vaccine X"},{"key":"10.1016\/j.vaccine.2026.128689_bb0095","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1109\/WSC63780.2024.10838944","article-title":"Quantifying the impact of vaccinating under-immunized groups in polio outbreaks: a simulation-based study","volume":"2024","author":"Sun","year":"2024","journal-title":"Winter Simul Conf (WSC)"},{"key":"10.1016\/j.vaccine.2026.128689_bb0100","author":"World Health Organization"},{"issue":"8","key":"10.1016\/j.vaccine.2026.128689_bb0105","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/S1473-3099(15)00094-8","article-title":"Immunogenicity of three doses of bivalent, trivalent, or type 1 monovalent oral poliovirus vaccines with a 2 week interval between doses in Bangladesh: an open-label, non-inferiority, randomised, controlled trial","volume":"15","author":"Est\u00edvariz","year":"2015","journal-title":"Lancet Infect Dis"},{"issue":"suppl_1","key":"10.1016\/j.vaccine.2026.128689_bb0110","doi-asserted-by":"crossref","first-page":"S439","DOI":"10.1093\/infdis\/jit601","article-title":"Immunogenicity and effectiveness of routine immunization with 1 or 2 doses of inactivated poliovirus vaccine: systematic review and meta-analysis","volume":"210","author":"Grassly","year":"2014","journal-title":"J Infect Dis"},{"issue":"8","key":"10.1016\/j.vaccine.2026.128689_bb0115","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/S1473-3099(20)30693-9","article-title":"Fractional dose compared with standard dose inactivated poliovirus vaccine in children: a systematic review and meta-analysis","volume":"21","author":"Mashunye","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128689_bb0120","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1093\/oxfordjournals.aje.a115009","article-title":"Serologic response to oral polio vaccine and enhanced-potency inactivated polio vaccines","volume":"128","author":"McBean","year":"1988","journal-title":"Am J Epidemiol"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128689_bb0125","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1186\/s12985-025-02977-3","article-title":"Immunogenicity and safety of polio vaccines in infants: a systematic review of randomized clinical trials","volume":"22","author":"Terekhov","year":"2025","journal-title":"Virol J"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128689_bb0130","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/j.1539-6924.2012.01864.x","article-title":"Expert review on poliovirus immunity and transmission","volume":"33","author":"Duintjer Tebbens","year":"2013","journal-title":"Risk Anal"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128689_bb0135","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/risa.12031","article-title":"Review and assessment of poliovirus immunity and transmission: synthesis of knowledge gaps and identification of research needs","volume":"33","author":"Duintjer Tebbens","year":"2013","journal-title":"Risk Anal"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128689_bb0140","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/risa.12044","article-title":"Characterizing poliovirus transmission and evolution: insights from modeling experiences with wild and vaccine-related polioviruses","volume":"33","author":"Duintjer Tebbens","year":"2013","journal-title":"Risk Anal"},{"key":"10.1016\/j.vaccine.2026.128689_bb0145","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/risa.13447","article-title":"Global transmission of live polioviruses: updated dynamic modeling of the polio endgame","volume":"41","author":"Kalkowska","year":"2020","journal-title":"Risk Anal"},{"issue":"12","key":"10.1016\/j.vaccine.2026.128689_bb0150","article-title":"Monitoring the risk of type-2 circulating vaccine-derived poliovirus emergence during roll-out of type-2 novel oral polio vaccine","volume":"12","author":"Peak","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2026.128689_bb0155","doi-asserted-by":"crossref","first-page":"A12","DOI":"10.1016\/j.vaccine.2021.04.026","article-title":"The impact of disruptions caused by the COVID-19 pandemic on global polio eradication","volume":"41","author":"Kalkowska","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128689_bb0160","author":"The U.S. Agency for International Development"},{"key":"10.1016\/j.vaccine.2026.128689_bb0165","author":"National Population Commission of Nigeria"},{"key":"10.1016\/j.vaccine.2026.128689_bb0170","author":"Institute for Health Metrics and Evaluation (IHME)"},{"issue":"6489","key":"10.1016\/j.vaccine.2026.128689_bb0175","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1126\/science.aba1238","article-title":"Evolving epidemiology of poliovirus serotype 2 following withdrawal of the serotype 2 oral poliovirus vaccine","volume":"368","author":"Macklin","year":"2020","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128689_bb0180","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1080\/14760584.2024.2361060","article-title":"Evolution of global polio eradication strategies: targets, vaccines, and supplemental immunization activities (SIAs)","volume":"23","author":"Thompson","year":"2024","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2026.128689_bb0185","doi-asserted-by":"crossref","first-page":"1098419","DOI":"10.3389\/fpubh.2023.1098419","article-title":"Looking back at prospective modeling of outbreak response strategies for managing global type 2 oral poliovirus vaccine (OPV2) cessation","volume":"11","author":"Thompson","year":"2023","journal-title":"Front Public Health"},{"issue":"8","key":"10.1016\/j.vaccine.2026.128689_bb0190","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1080\/14760584.2018.1506333","article-title":"Polio endgame risks and the possibility of restarting the use of oral poliovirus vaccine","volume":"17","author":"Duintjer Tebbens","year":"2018","journal-title":"Expert Rev Vaccines"},{"issue":"suppl_1","key":"10.1016\/j.vaccine.2026.128689_bb0195","doi-asserted-by":"crossref","first-page":"S168","DOI":"10.1093\/infdis\/jix128","article-title":"Lessons from globally coordinated cessation of serotype 2 oral poliovirus vaccine for the remaining serotypes","volume":"216","author":"Thompson","year":"2017","journal-title":"J Infect Dis"},{"issue":"Suppl. 1","key":"10.1016\/j.vaccine.2026.128689_bb0200","doi-asserted-by":"crossref","first-page":"S475","DOI":"10.1093\/infdis\/jit845","article-title":"Modeling the dynamics of oral poliovirus vaccine cessation","volume":"210","author":"Thompson","year":"2014","journal-title":"J Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128689_bb0205","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1111\/j.1539-6924.2006.00843.x","article-title":"Evaluation of response scenarios to potential polio outbreaks using mathematical models","volume":"26","author":"Thompson","year":"2006","journal-title":"Risk Anal"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128689_bb0210","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1093\/infdis\/jiad222","article-title":"Impact of supplementary immunization activities using novel oral polio vaccine type 2 during a large outbreak of circulating vaccine-derived poliovirus in Nigeria","volume":"229","author":"Voorman","year":"2024","journal-title":"J Infect Dis"},{"issue":"100","key":"10.1016\/j.vaccine.2026.128689_bb0215","first-page":"605","article-title":"Meeting of the strategic advisory Group of Experts on immunization, September 2025: conclusions and recommendations","volume":"49","author":"World Health Organization","year":"2025","journal-title":"Wkly Epidemiol Rec"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128689_bb0220","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/risa.14159","article-title":"Worst-case scenarios: modeling uncontrolled type 2 polio transmission","volume":"44","author":"Kalkowska","year":"2024","journal-title":"Risk Anal"},{"key":"10.1016\/j.vaccine.2026.128689_bb0225","doi-asserted-by":"crossref","DOI":"10.12688\/gatesopenres.14511.1","article-title":"Complexity of options related to restarting oral poliovirus vaccine (OPV) in national immunization programs after OPV cessation","volume":"7","author":"Kalkowska","year":"2023","journal-title":"Gates Open Res"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128689_bb0230","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/risa.13555","article-title":"Updated characterization of post-OPV cessation risks: lessons from 2019 serotype 2 outbreaks and implications for the probability of OPV restart","volume":"41","author":"Kalkowska","year":"2021","journal-title":"Risk Anal"},{"issue":"7","key":"10.1016\/j.vaccine.2026.128689_bb0235","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1080\/14760584.2019.1635463","article-title":"Logistical challenges and assumptions for modeling the failure of global cessation of oral poliovirus vaccine (OPV)","volume":"18","author":"Thompson","year":"2019","journal-title":"Expert Rev Vaccines"},{"issue":"9","key":"10.1016\/j.vaccine.2026.128689_bb0240","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/S1473-3099(23)00139-1","article-title":"Immunogenicity of novel oral poliovirus vaccine type 2 administered concomitantly with bivalent oral poliovirus vaccine: an open-label, non-inferiority, randomised, controlled trial","volume":"23","author":"Wilkinson","year":"2023","journal-title":"Lancet Infect Dis"},{"issue":"9","key":"10.1016\/j.vaccine.2026.128689_bb0245","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines12091006","article-title":"Population movement and poliovirus spread across Pakistan and Afghanistan in 2023","volume":"12","author":"Sodhar","year":"2024","journal-title":"Vaccines"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128689_bb0250","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12879-015-0791-5","article-title":"Modeling undetected live poliovirus circulation after apparent interruption of transmission: implications for surveillance and vaccination","volume":"15","author":"Kalkowska","year":"2015","journal-title":"BMC Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128689_bb0255","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/risa.13486","article-title":"[72] modeling undetected live poliovirus circulation after apparent interruption of transmission: Borno and Yobe in Northeast Nigeria","volume":"41","author":"Kalkowska","year":"2021","journal-title":"Risk Anal"},{"issue":"9","key":"10.1016\/j.vaccine.2026.128689_bb0260","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1093\/aje\/kwr399","article-title":"[85] The probability of undetected wild poliovirus circulation after apparent global interruption of transmission","volume":"175","author":"Kalkowska","year":"2012","journal-title":"Am J Epidemiol"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128689_bb0265","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S1473-3099(23)00688-6","article-title":"Effectiveness of poliovirus vaccines against circulating vaccine-derived type 2 poliomyelitis in Nigeria between 2017 and 2022: a case-control study","volume":"24","author":"Cooper","year":"2024","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128689_bb0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanmic.2024.101028","article-title":"Intestinal mucosal immune responses induced by novel oral poliovirus vaccine type 2 and Sabin monovalent oral poliovirus vaccine type 2: an analysis of data from four clinical trials","volume":"6","author":"Godin","year":"2025","journal-title":"The Lancet Microbe"},{"key":"10.1016\/j.vaccine.2026.128689_bb0275","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3390\/pathogens13040273","article-title":"Novel oral polio vaccine type 2 use for polio outbreak response: a global effort for a global health emergency","volume":"13","author":"Kurji","year":"2024","journal-title":"Pathogens"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128689_bb0280","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1471-2334-14-45","article-title":"The potential impact of expanding target age groups for polio immunization campaigns","volume":"14","author":"Duintjer Tebbens","year":"2014","journal-title":"BMC Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2026.128689_bb0285","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1080\/14760584.2020.1791093","article-title":"Review of poliovirus modeling performed from 2000 to 2019 to support global polio eradication","volume":"19","author":"Thompson","year":"2020","journal-title":"Expert Rev Vaccines"},{"issue":"suppl_1","key":"10.1016\/j.vaccine.2026.128689_bb0290","doi-asserted-by":"crossref","first-page":"S412","DOI":"10.1093\/infdis\/jit834","article-title":"Modeling strategies to increase population immunity and prevent poliovirus transmission in the high-risk area of Northwest Nigeria","volume":"210","author":"Kalkowska","year":"2014","journal-title":"J Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128689_bb0295","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0130123","article-title":"Combinations of quality and frequency of immunization activities to stop and prevent poliovirus transmission in the high-risk area of Northwest Nigeria","volume":"10","author":"Duintjer Tebbens","year":"2015","journal-title":"PLoS One"},{"issue":"suppl_1","key":"10.1016\/j.vaccine.2026.128689_bb0300","doi-asserted-by":"crossref","first-page":"S176","DOI":"10.1093\/infdis\/jix108","article-title":"Lessons from the polio endgame: overcoming the failure to vaccinate and the role of subpopulations in maintaining transmission","volume":"216","author":"Thompson","year":"2017","journal-title":"J Infect Dis"},{"issue":"8","key":"10.1016\/j.vaccine.2026.128689_bb0305","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1111\/risa.12962","article-title":"Modeling poliovirus transmission in Pakistan and Afghanistan to inform vaccination strategies in undervaccinated subpopulations","volume":"38","author":"Duintjer Tebbens","year":"2018","journal-title":"Risk Anal"},{"issue":"suppl_1","key":"10.1016\/j.vaccine.2026.128689_bb0310","doi-asserted-by":"crossref","first-page":"S398","DOI":"10.1093\/infdis\/jit844","article-title":"Modeling strategies to increase population immunity and prevent poliovirus transmission in 2 high-risk areas in northern India","volume":"210","author":"Kalkowska","year":"2014","journal-title":"J Infect Dis"},{"issue":"suppl_1","key":"10.1016\/j.vaccine.2026.128689_bb0315","doi-asserted-by":"crossref","first-page":"S98","DOI":"10.1093\/infdis\/jit285","article-title":"Using geographic information systems to track polio vaccination team performance: pilot project report","volume":"210","author":"Gammino","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128689_bb0320","author":"Global Polio Eradication Initiative"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26004974?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26004974?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T22:28:59Z","timestamp":1783290539000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26004974"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":64,"alternative-id":["S0264410X26004974"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128689","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quantifying the benefits of improved operations for polio outbreak response: A model-based analysis","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128689","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"128689"}}